Kevin Kunzmann

Dr. Castro and Dr. Rizzo discuss the evolving world of monoclonal antibodies for severe asthma. Plus, the ALA team discusses September's annual Asthma Peak Week, and what it means for reopening schools.

Now that the agent shows benefit in mitigating comorbid risks, the expert advocates for more timely diagnoses and treatment initiation.

The direct-acting oral anticoagulant benefitted prevention of adverse clinical events, but was associated with worse major bleeding.

New EMPEROR-Preserved findings show the SGLT-2 inhibitor significantly reduced heart failure-related hospitalizations, regardless of patient diabetes status.

The newest indication for the anticoagulant is based on phase 3 VOYAGER PAD findings showing benefit in reduced risk of major cardiovascular events among post-revascularization patients with PAD.

The BNT162b2 vaccine is the first to be approved by the FDA, and will likely result in greater prescribing capability and workplace vaccine mandates.

A new study showed about half of all vitiligo patients from a care system were burdened with the sleeping disorder.

For World Breastfeeding Week, a lactation consultant explains Montefiore's care team strategies and guidance to expecting and new mothers.

The issuance comes within a week of the planned PDUFA date for the drug's possible indication as an adult CKD therapy.

The co-founder and CEO of Known Medicine dissects the art and science of how profiling biomarkers, epigenetics and the microenvironment may provide the synergy needed to revolutionize the oncologic landscape.

New findings show patients were able to more than halve type 2 diabetes medication while improving diabetic and cardiovascular parameters in 8 weeks.

New SUPRASS-2 findings show the dual GIP/GLP-1 agonist provided superior type 2 diabetes management outcomes at 3 different doses.

A comparison of 3 standard dietary strategies for weight and glycemia control showed no difference in exercise metrics.

The study author joins to highlight new ADA 2021 findings showing rivaroxaban's benefit for a subpopulation of diabetic patients.

Dabigatran etexilate was approved in both oral pellet and capsule forms for varying pediatric patient populations.

The National Institutes of Health expert and research joins to discuss the evolving understanding of vaping devices and effects.

Results from the PREVENT-19 trial show the vaccine yields a 90% efficacy rate against symptomatic disease.

Hematopoietic stem cell transplant is generally associated with increased C difficile infection risk.

The expansion for sofosbuvir/velpatasvir is supported by phase 2 data showing an 83% sustained virologic response or cure rate among patients as young as 3 years old.

The new indication for the therapy provides coverage for patients with the rare blood disease as young as 1 month old.

The indication makes the Novo Nordisk product the first weekly injection GLP-1 agonist approved for managing overweight and obesity.

A survey at ACC 2021 showed 38% of cardiology professionals were burnt out during COVID-19. What factors in the field have already made it difficult to cope?

The high-risk patient population is under-represented in new research and agents. Why characteristics set it apart from other cardiovascular diseases?

New data suggest 90 days following an initial ACS event is the greatest time of likelihood for another high-risk event. How can this inform cardiovascular research?

Marc Bonaca, MD, explains the value of new assessments made in the pivotal peripheral artery disease clinical trial.

A cardiologist and wellness expert discusses new findings showing more than one-third of her peers were burnt out from experiences during the pandemic.

Investigators discuss recently-published secondary sex-based assessments into PCI treatment, as well as their contribution to cardiovascular research action points that lessen the field's disparities.

DARE-19 data show a slight improvement in outcomes among hospitalized COVID-19 patients receiving the SGLT-2 inhibitor—showing the cardiovascular drug class is safe in patients with the pandemic virus.

The SGLT-2 inhibitor drug class is expanding into treatment indications experts could not have predicted. Learn how DAPA-HF contributed to the understanding of dapagliflozin.

Investigators discuss observed outcomes in females with high-risk PCI treatment, and their continued underrepresentation in pharmacologic studies.